The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels.

Introduction: Prostate-specific membrane antigen (PSMA) is increasingly being recognized as a novel target for the PET imaging of prostate cancer (PCa) and Ga-DKFZ-11 (Ga-PSMA) has been suggested as a novel tracer for detection of PCa relapses and metastases. The aim of this study was to evaluate the diagnostic value of PSMA PET/CT in the diagnosis of recurrent PCa with low prostate-specific antigen (PSA) levels.

Patients And Methods: We carried out a retrospective analysis of patients who underwent PSMA PET/CT from November 2013 to December 2014 in our department.

Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET/CT imaging.

Purpose: Ga-PSMA-11 is a novel PET tracer suggested to be used for imaging of advanced prostate cancer. In this study, we aimed to present a detailed biodistribution of Ga-PSMA-11, including physiological and benign variants of prostate-specific membrane antigen (PSMA) imaging.

Materials And Methods: We carried out a retrospective analysis of 40 patients who underwent PSMA PET/computed tomography (CT) imaging and who had no evidence of residual or metastatic disease on the scans.

Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging.

Purpose: The aim of the study was to evaluate the diagnostic value of the prostate-specific membrane antigen (PSMA) ligand (68)Ga-HBED-CC (PSMA PET/CT) in patients with prostate cancer and evaluate the value of early imaging of the pelvis.

Materials And Methods: The files of 28 patients were retrospectively evaluated. All patients had a histopatological confirmation of prostate cancer.